Condition (MeSH)
Adenocarcinoma, Papillary
ClinicalTrials.gov lists 186 trials for Adenocarcinoma, Papillary or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 19.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
3 of the 186 trials are tagged with Adenocarcinoma, Papillary itself; the rest are tagged with a narrower condition beneath it.
When did Adenocarcinoma, Papillary trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 17
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 12 |
| 2025 | 12 |
| 2024 | 17 |
| 2023 | 7 |
| 2022 | 12 |
| 2021 | 14 |
| 2020 | 11 |
| 2019 | 6 |
| 2018 | 9 |
| 2017 | 3 |
Showing 10 of 30 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 13 trials starting in 2026 and about 13 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 99 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adenocarcinoma, Papillary trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 17 |
| Phase 1/2 | 7 |
| Phase 2 | 43 |
| Phase 2/3 | 3 |
| Phase 3 | 5 |
| Phase 4 | 2 |
| Not applicable | 44 |
| Observational | 64 |
| Expanded access | 1 |
How many Adenocarcinoma, Papillary trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 15 |
| Recruiting | 27 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 17 |
| Completed | 81 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adenocarcinoma, Papillary trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 19 |
| Hoffmann-La Roche | 4 |
| Eli Lilly and Company | 3 |
| Exelixis | 3 |
| National Cancer Center, Korea | 3 |
Which drugs are being tested for Adenocarcinoma, Papillary? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sodium Iodine I-131 | 7 |
| Selpercatinib | 5 |
| GSK1120212 | 4 |
| Dabrafenib | 4 |
| 18F-FDG | 3 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Positron Emission Tomography (PET) | 7 |
| Vermurafenib | 4 |
| Sunitinib 4/2 | 3 |
| Lenvatinib 1 | 3 |
| ZD6474, Vandetanib | 2 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adenocarcinoma, Papillary trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 281 | 6 |
| Pleural effusion | 106 | 11 |
| Sepsis | 103 | 5 |
| Dyspnoea | 88 | 3 |
| Abdominal pain | 82 | 10 |
Showing 5 of 10 adverse events.
Which publications cover Adenocarcinoma, Papillary? (31)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. | Cancer discovery | 2022 | Yes |
| A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer. | BMJ open | 2018 | Yes |
| Robotic and open partial nephrectomy for complex renal tumors: a matched-pair comparison with a long-term follow-up. | World journal of urology | 2017 | Yes |
| Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring ≤3 cm. | Anticancer research | 2016 | Yes |
| The vessels within epithelial circle (VEC) pattern as visualized by magnifying endoscopy with narrow-band imaging (ME-NBI) is a useful marker for the diagnosis of papillary adenocarcinoma: a case-controlled study. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2014 | Yes |
Showing 5 of 31 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.